Abstract
Postconditioning (postcon) protects the heart from ischemia reperfusion (IR) injury. Protease activated receptor1 (PAR1) inhibition has protective effects after IR. Therefore, we hypothesize that if postcon and pharmacological PAR1 inhibition target the same pathway, and the combination of postcon and PAR1 inhibition may not have additive protective effect.MethodsIn anesthetized open‐chest rats, the left coronary artery (LCA) was occluded for 30 min and reperfused for 3 hours. Rats were randomly assigned to1) Control: saline; 2) PAR1 antagonist (BMS 226001) 1mg/Kg was administered 5 min before R; 3) Postcon with 3 cycles of 10 s R and 10 s re‐occlusion and 4) BMS 1 mg/Kg plus postcon.ResultsArea at risk (36%–39%) was comparable among 4 groups. Compared to control, infarct size (TTC staining) was significantly less in BMS, postcon and the combination groups. The combination of BMS and postcon did not further significantly reduce infarct size compared to either intervention alone.ConclusionsInhibition of PAR1 and postcon alone at reperfusion are cardioprotective in vivo; however, concomitant PAR1 inhibition does not enhance the cardioprotection of postcon. Group N AAR/LV (%) An/AAR (%) Control 7 37.9 ± 2.4 57.0 ± 2.1 BMS 8 38.1 ± 2.5 42.5 ± 2.5* Postcon 7 39.3 ± 2.1 39.1 ± 2.3* BMS + Postcon 7 35.6 ± 1.4 39.9 ± 3.0* Values are expressed as mean ± S.E.M. P < 0.05 vs. values in control.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
